SMC rejects Janssen’s multiple myeloma treatment Darzalex
January 17, 2017Manufacturing and Production, Sales and Marketing Janssen, SMC, darzalex
The Scottish Medicines Consortium (SMC) has decided not to recommend Janssen’s Darzalex (daratumumab) for routine use by NHS Scotland as …
Merck forges data analytics partnership with Palantir
January 17, 2017Manufacturing and Production, Research and Development, Sales and Marketing Merck, Palantir
Merck has teamed up with software and data-mining firm Palantir with the intention to utilise its data analytics services to …
AZ to rework ongoing immuno-oncology trials to “enhance options”
January 17, 2017Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, non-small cell lung cancer
Due to the “strong efficacy” shown by its durvalumab as a treatment for non-small cell lung cancer (NSCLC), AstraZeneca has …
New NICE ultra-rare disease proposals “not fit for purpose”, says BIA
January 16, 2017Manufacturing and Production BioIndustry Association, NICE
The BioIndustry Association (BIA) has accused new proposals put forward by the National Institute for Health and Care Excellence (NICE) …
Benzodiazepines increase stroke risk in Alzheimer’s patients, study finds
January 16, 2017Research and Development, Sales and Marketing Alzheimer's, Alzheimers, benzodiazepines
Benzodiazepines and similar drugs could increase the risk of strokes in Alzheimer’s patients by as much as 20% according to …
J&J to reveal drug price increases next month
January 16, 2017Sales and Marketing Johnson & Johnson
Next month, Johnson & Johnson will reveal the average price increases of its prescription drugs in a move to increase …
Novo strikes up personalised diabetes treatment deal with Glooko
January 16, 2017Sales and Marketing Glooko, Novo Nordisk, ibm
Novo Nordisk has entered into a partnership with Californian firm Glooko to develop a number of offerings to aid with …
Merck in $230 million swoop for Vertex cancer programmes
January 16, 2017Sales and Marketing Vertex
Merck has completed a deal with Boston-based biotech firm Vertex Pharmaceuticals for the rights to four cancer programmes worth $230 …
Top Ten most popular articles on Pharmafile.com this week
January 13, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing top ten
We’re now into 2017 in earnest and news of acquisitions, partnerships, R&D advancements and scandals are back in force. Cancer …
Advancing the Pharmaceutical Supply Chain
January 13, 2017Manufacturing and Production, Medical Communications Janssen, batch manufacturing, continuous manufacturing
Mauricio Futran, vice president, Process Sciences, Janssen Supply Chain, discusses, in the latest issue of Pharmafile, Janssen’s move into continuous …
Lilly three strikes in three years not out in Teva patent challenge
January 13, 2017Medical Communications, Sales and Marketing Eli Lilly, Teva, generics, lilly, patent
Eli Lilly has successfully won a major patent case against Teva Pharmaceuticals, with the case being decided at the US …
NICE recommends Novartis’ previously CDF-exclusive kidney cancer treatment
January 13, 2017Medical Communications, Sales and Marketing Afinitor, CDF, NICE, Novartis, everolimus
In a reappraisal decision by NICE, everolimus (Novartis’ Afinitor) has been recommended for the treatment of advanced renal cell carcinoma …
Welsh government launches £80 million fund for newly approved drugs
January 13, 2017Medical Communications Wales, Welsh Government, drug fund
The Welsh Government has created a five-year £80 million drug fund, which will work out to an additional £16 million …
Drugstore chain CVS offers EpiPen generic for 600% cheaper
January 12, 2017Medical Communications, Sales and Marketing CVS, Mylan, epipen
The Mylan EpiPen scandal was one of last year’s most closely-followed stories, as the industry reacted with scorn to CEO …
IBM and FDA collaborate to protect patient data with blockchain technology
January 12, 2017Medical Communications, Research and Development FDA, blockchain, blockchain technology, ibm
IBM Watson Health has agreed a research initiative with the FDA to develop and test the exchange of patients’ health …
Takeda invests $125m in Maverick T-cell platform partnership
January 12, 2017Research and Development Maverick, Takeda
Takeda has announced its intention to invest $125 million in a partnership with Maverick Therapeutics to develop the latter’s T-cell …
Mylan and Biocon apply to FDA for biosimilar approval
January 12, 2017Sales and Marketing Biocon, FDA, Mylan, biosimilar, trastuzumab
Mylan, the US-based generics specialist, and Biocon, an Indian biopharmaceutical company, have applied for a biologics license application (BLA) for …
Shire fined $350 million in largest-ever bribery case of its kind
January 12, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Shire. Department of Justice
Shire Pharmaceuticals is set to pay a $350 million settlement over accusations that it had bribed clinicians and physicians by …
New immunotherapy-based cancer research limits cancer spread by 75%
January 12, 2017Medical Communications, Research and Development Cancer, cancer research, immunotherapy
Research conducted by the Sanger Institute in Cambridge has discovered 23 new genes associated with cancer cell’s spread through the …
Rio De Janeiro’s primary airport awarded CEIV Pharma certification
January 11, 2017Manufacturing and Production Rio Galeao, cargo
Rio Galeão, the main airport serving Rio De Janeiro, has been awarded Centre of Excellence for Independent Validators (CEIV) Pharma …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
